Home » Stocks » PIRS

Pieris Pharmaceuticals, Inc. (PIRS)

Stock Price: $2.68 USD -0.04 (-1.47%)
Updated Mar 3, 2021 10:29 AM EST - Market open
Market Cap 156.72M
Revenue (ttm) 44.72M
Net Income (ttm) -26.43M
Shares Out 54.34M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $2.68
Previous Close $2.72
Change ($) -0.04
Change (%) -1.47%
Day's Open 2.72
Day's Range 2.61 - 2.80
Day's Volume 97,566
52-Week Range 1.60 - 3.64

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 1 month ago

BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Antical...

Seeking Alpha - 3 months ago

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of -62.50% and -67.29%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead ...

Benzinga - 3 months ago

  Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q3 results.

Seeking Alpha - 6 months ago

Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 8% in pre-market trading after the company reported Q2 results.

PRNewsWire - 7 months ago

NEW YORK, July 21, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Pieris Pharmaceuticals, Inc. ("Pieris" or the "Company") (NASDAQ: PIRS).

Seeking Alpha - 9 months ago

Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.25% and 40.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 10 months ago

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 11 months ago

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Other stocks mentioned: MGTX, NTLA, QURE, VRTX, GNOM
Zacks Investment Research - 1 year ago

Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.

Other stocks mentioned: MGTX, NTLA, QURE, VRTX
Seeking Alpha - 1 year ago

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 78.26% and 141.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead f...

Seeking Alpha - 1 year ago

The stock of Pieris Pharmaceuticals has made a nice move so far in September.

Seeking Alpha - 1 year ago

Pieris Pharmaceuticals' (PIRS) CEO Steve Yoder on Q2 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Here are four stocks that appear to be at or near a breakout point: Enphase Energy, Inc.

Other stocks mentioned: ENPH, QD, TAL
Zacks Investment Research - 1 year ago

Investors need to pay close attention to Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Shares have fallen by 30% since my initial and update articles.

Seeking Alpha - 1 year ago

Pieris Pharmaceuticals, Inc. (PIRS) CEO Stephen Yoder on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About PIRS

Pieris Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and ... [Read more...]

Industry
Biotechnology
CEO
Stephen Yoder
Employees
114
Stock Exchange
NASDAQ
Ticker Symbol
PIRS
Full Company Profile

Financial Performance

In 2019, PIRS's revenue was $46.28 million, an increase of 59.03% compared to the previous year's $29.10 million. Losses were -$25.47 million, -4.80% less than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for PIRS stock is "Strong Buy." The 12-month stock price forecast is 9.00, which is an increase of 235.82% from the latest price.

Price Target
$9.00
(235.82% upside)
Analyst Consensus: Strong Buy